Mankind Pharma to Invest Rs 2.99 crore in Sri Lankan Subsidiary
By Ankur Chandra | Updated at: May 31, 2025 10:45 PM IST
Mankind Pharma Limited has announced the incorporation of a new wholly-owned subsidiary (WOS) in Sri Lanka, aimed at expanding its footprint in the international pharmaceutical market. The acquisition-related disclosure, filed under Regulation 30 of SEBI (LODR) norms, outlines the company’s plan to invest USD 350,000 (approximately ₹2.99 crore) in setting up the entity.
Acquisition Highlights
| Particulars | Details |
|---|---|
| Target Entity | Yet to be named; to be approved by the Sri Lankan authorities |
| Industry | Pharmaceutical |
| Country of Incorporation | Sri Lanka |
| Proposed Investment | USD $350,000 (₹2.99 crore) |
| Shareholding Post-Acquisition | 100% by Mankind Pharma |
| Nature of Consideration | Subscription to equity shares of the proposed subsidiary |
| Mode of Funding | Internal accruals |
| Transaction Type | New Incorporation (not an acquisition of an existing entity) |
| Tranches | Investment to be made in one or more tranches |
| RPT Classification | Not a Related Party Transaction |
| Arm’s Length Transaction | Yes |
Objectives of the Acquisition
The proposed WOS in Sri Lanka will undertake the business of import, trading, promotion, marketing, distribution, and contract manufacturing of both pharmaceutical and over-the-counter (OTC) products. This strategic move is aligned with Mankind Pharma’s long-term vision of enhancing its global presence, particularly in high-potential emerging markets.
The company disclosed that the acquisition is not a related party transaction, and has been negotiated on an arms length basis. At present, the WOS has nil turnover, profit, and net worth as the subsidiary has not been incorporated yet. This extension is in addition to Mankind Pharma’s desire to capitalize regional market outside India and to meet an increasing demand in South Asia.
Regulatory Approvals
Mankind Pharma confirmed that the WOS incorporation is subject to approvals under the Foreign Exchange Management Act (FEMA), Reserve Bank of India (RBI) regulations, and regulatory permissions from authorities in Sri Lanka.
Management Outlook
In its filing, the company stated, Post incorporation, Mankind Pharma Limited would be, directly or indirectly, holding 100% share capital of this new Company. The investment is aimed at meeting set-up, initial operating, procurement, and other costs associated with launching pharmaceutical operations in Sri Lanka.”
Future Outlook
With this step, Mankind Pharma aims to strengthen its position in the global pharmaceutical value chain, particularly through strategic investments in emerging economies. Sri Lanka is viewed as a gateway to broader South Asian markets, making this move a calculated bet for long-term growth.
Stock Performance:
Mankind Pharma shares have gained 21% in the last year, and a 2.26% dip in the last month.
About Mankind Pharma
Founded in 1991, Mankind Pharma is one of India’s leading pharmaceutical companies, offering a diverse product portfolio that includes prescription medicines, OTC products, diagnostics, and wellness solutions. The company went public in 2023 and has consistently maintained strong financials and investor confidence.
Disclaimer: This content is only for informational purpose. It does not make any recommendation to act or invest. The content is based on highly reliable resources. Still if there is any error it is deeply regretted. Write to us for getting any error corrected.
REF: https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_1446182_21052025072620_WEB.xml
